Embecta (NASDAQ:EMBC) Hits New 52-Week Low – Here’s What Happened

Embecta Corp. (NASDAQ:EMBC)’s share price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $9.06 and last traded at $9.18, with a volume of 111157 shares. The stock had previously closed at $9.44.

Analyst Ratings Changes

EMBC has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, BTIG Research reissued a “buy” rating and issued a $25.00 price target on shares of Embecta in a report on Friday, February 6th. One research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Embecta has an average rating of “Hold” and an average price target of $18.50.

Embecta Trading Down 3.9%

The stock’s 50 day simple moving average is $11.08 and its 200 day simple moving average is $12.75. The stock has a market capitalization of $537.13 million, a P/E ratio of 3.83 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.67 by $0.04. The business had revenue of $261.20 million for the quarter, compared to analysts’ expectations of $258.07 million. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company posted $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, sell-side analysts expect that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th will be given a $0.15 dividend. The ex-dividend date is Friday, February 27th. This represents a $0.60 annualized dividend and a dividend yield of 6.6%. Embecta’s dividend payout ratio (DPR) is presently 25.32%.

Hedge Funds Weigh In On Embecta

Several large investors have recently added to or reduced their stakes in the company. Alpine Global Management LLC acquired a new position in Embecta in the fourth quarter worth $178,000. River Road Asset Management LLC lifted its position in shares of Embecta by 5.3% in the 4th quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock worth $40,587,000 after buying an additional 171,194 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Embecta by 49.3% in the 4th quarter. Pacer Advisors Inc. now owns 16,526 shares of the company’s stock worth $196,000 after buying an additional 5,460 shares during the last quarter. State of Tennessee Department of Treasury boosted its holdings in shares of Embecta by 23.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 53,290 shares of the company’s stock valued at $633,000 after buying an additional 10,263 shares during the period. Finally, Mackenzie Financial Corp grew its position in shares of Embecta by 34.0% during the 4th quarter. Mackenzie Financial Corp now owns 135,085 shares of the company’s stock valued at $1,627,000 after buying an additional 34,240 shares during the last quarter. 93.83% of the stock is currently owned by institutional investors.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.